Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →More from Wedica
Other strengths and forms by Beacon Pharmaceuticals PLC
Indications & Uses
Trelagliptin Succinate is used for type 2 diabetes mellitus. Doctors prescribe it when metformin, the first line treatment, has not brought blood sugar down to the expected glycemic goals.
Pharmacology
Trelagliptin inhibits the activity of dipeptidyl peptidase 4. After a person eats, glucagon-like peptide 1 (GLP-1) is secreted from the intestines into the blood, and this inhibition stops it from being inactivated. The GLP-1 concentration in the blood rises, and the pancreas then releases insulin depending on the blood glucose concentration.
DPP-4 Inhibition
Trelagliptin selectively inhibits human plasma DPP-4 activity (IC50 value: 4.2 nmol/l, in vitro). Trelagliptin and alogliptin were also compared for DPP-4 inhibitory action under similar conditions (in vitro), and their IC50 values (nmol/L) were 1.3 and 5.3 respectively. In a study, type 2 diabetes patients whose blood glucose was not controlled well enough by diet and exercise took 100 mg of Trelagliptin once weekly, before meal, for 12 weeks. The study was double blind, parallel group and placebo controlled. The average DPP-4 inhibition rate 7 days after the final treatment was 77.4% in the Trelagliptin 100 mg group.
Active Type GLP-1 Concentration Elevation
Type 2 diabetes patients whose blood glucose was not controlled well enough by diet and exercise took 100 mg of Trelagliptin orally, once weekly, before meal, for 12 weeks. This was also a double-blind, parallel group, placebo-controlled comparative study. Meal load tests done 12 weeks after administration showed GLP-1 concentrations that were significantly elevated compared with the placebo group.
Glucose Tolerance Improvement
A single oral dose of Trelagliptin was given to obese type 2 diabetic model organisms (Wister fatty rat) and to non-obese type 2 diabetic model organisms (N-STZ-1.5 rat) after 1 night of fasting. Glucose was then given orally 1 hour after the drug, as a glucose load test. The results showed that Trelagliptin improves glucose tolerance.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Adults take Trelagliptin 100 mg by mouth once a week.
Cautions Related to Methods and Dose
In patients with moderate kidney function disease, the blood level of the medicine rises because the body clears it more slowly. So the dose should be reduced, using the chart below as a guide.
Instruct the patient on the following points. Trelagliptin is taken once a week, and on the same day every week. If the patient forgets a dose, they should take only the amount meant for the time the missed dose is noticed, and then carry on with a newly decided schedule from that point.
Side Effects
Among 901 domestic clinical trial cases up to the time of approval, 103 cases (11.4%) showed clinical results that included abnormalities and side effects. These were mainly hypoglycemia, nasopharyngitis and elevated lipase. Serious side effects such as hypoglycemia (0.1 to 5%) can appear, so give the medicine while closely observing the patient's status. Other DPP-4 inhibitors have been reported to cause serious hypoglycemia when used together with sulfonylurea medicines, and there were some cases of loss of consciousness. If a drop in blood sugar from this medicine is confirmed, it can be remedied by giving sucrose. But hypoglycemia that comes from a combination with glucosidase inhibitors should be treated with fructose. Acute pancreatitis can occur, so observe the patient carefully. If sustained, intense abdominal pain, vomiting or other abnormal symptoms appear, stop the drug and take appropriate measures. Intestinal obstruction can also occur, so observe carefully. If severe constipation, abdominal swelling, sustained abdominal pain, vomiting or other symptoms are seen, stop treatment and take appropriate measures. Other Side Effects Take appropriate actions depending on the situation if the following side effects arise. Administration to Elderly Patients Many elderly patients have lowered kidney function, so take note of side effects and give a cautious dose while observing treatment progress sufficiently. Administration to pregnant women, lactating women, or for gynecological use For women who are pregnant or may be pregnant, give the drug only after fully evaluating the risks and benefits of treatment. The safety of use during pregnancy is not established. There are reports of the drug crossing the placenta in animal (rat) tests. Avoid giving the drug to women who are breastfeeding, and if it must be given, stop breastfeeding. Administration to children The safety of Trelagliptin Succinate in infants with low birth weight, newborn infants, nursing infants, babies, and children under the age of 13 is not established. Overdose Safety information regarding overdose has not been sufficiently collected, for dietary and exercise treatments, as well as metformin-only treatments, or for type 2 diabetes patients whose blood sugar control is not ideal. However, there have been overseas studies in which lOOmg of Trelagliptin Succinate was taken orally every day over 12 consecutive weeks, and the side effects did not differ from the placebo group. Other warnings Overseas clinical studies involving single doses of 800mg of Trelagliptin Succinate reported QT elongation.
Cautions & Contraindications
Warnings & Precautions
Trelagliptin Succinate needs a cautious dose in the following patients: those with moderate kidney function disorder, those being treated with sulfonylurea drugs or insulin medicines (there are reports of severe hypotension when other DPP-4 inhibitors are used in combination), and those with hypopituitarism or hypoadrenalism. The same care applies in malnutrition, starvation, irregular eating patterns, insufficient eating or hyposthenia, with vigorous exercise, and in patients who consume excessive alcohol. Major Warnings Trelagliptin Succinate may cause hypoglycemia when it is used with other diabetes medicines. So explain this risk to the patient thoroughly, and caution them about hypoglycemia when it is combined with other medicines. The risk is higher particularly with sulfonylurea drugs and insulin medicines. When it is used together with these, consider reducing the dose of the sulfonylurea or insulin medicine to lessen the risk of hypoglycemia. Trelagliptin Succinate is taken orally once per week. Its effects may persist even after the dose is stopped, so pay sufficient attention to blood sugar values and side effects. Also, when other diabetes medicines are used after this medicine is stopped, evaluate the starting period and dose based on the state of blood sugar management. Only consider application for patients with an established diagnosis of diabetes mellitus. Pay attention to conditions that show abnormal sugar resistance, glucosuria and other symptoms resembling diabetes (renal glucosuria, thyroid function abnormality, etc.). Application of Trelagliptin Succinate should only be considered once diet and exercise based diabetes treatments have already been tried with unsatisfactory results. During treatment, progress should be observed sufficiently along with quantitative blood sugar measurements. If no results are seen after 2 to 3 months, consider changing to a more appropriate treatment method. During dose maintenance, the medicine may no longer be necessary, or its effects may diminish because of complications with poor nutrition or infectious disease. In such cases, evaluate whether to continue the normal dose and which medicine to choose, taking into account dietary volume, blood sugar levels and the presence of infectious symptoms. Warn patients who work in high places, operate machinery, etc., that low blood sugar can occur. Clinical results and safety of combining it with insulin medicines have not been investigated. Trelagliptin Succinate and GLP-1 receptor agonists both possess the ability to lower blood sugar and assist GLP-1 receptor agonists. There are no clinical study results on combining these medicines, and neither the efficacy nor the safety can be confirmed.
Contraindications
People who met any of the following criteria were not included in this study. These were patients already being treated with trelagliptin for type 2 diabetes when screening started, and patients diagnosed with type 1 diabetes. Patients with severe renal impairment or renal failure (for example, eGFR < 30 mL/min/1.73 m2 or on dialysis) were also left out. So were patients with serious heart disease or a cerebrovascular disorder, or a serious pancreatic, blood, or other disease. Patients with a history of gastrointestinal resection were excluded, as were those with proliferative diabetic retinopathy or malignancy. The same applied to patients with a history of hypersensitivity or allergy to DPP-4 inhibitors, and to patients who were pregnant, breast-feeding, possibly pregnant, or planning to become pregnant. Patients who might need to add or stop a concomitant medicine, or change its dose, during the study period were not included. Nor were patients who would need a prohibited concomitant medicine during the study period, patients taking part in other clinical studies, or patients the investigators judged ineligible for any other reason.
Pregnancy & Breastfeeding
No studies of Trelagliptin Succinate have been done in women who are pregnant, breast-feeding, possibly pregnant, or planning to become pregnant.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Storage
Store Trelagliptin Succinate at 25°C. Short periods between 15°C and 30°C are fine. Keep the tablets in the original container, because it protects them from high humidity and light. Keep the medicine out of the reach of children.
Common questions about Wedica 50 mg
What is Wedica 50 mg Tablet?
Wedica 50 mg Tablet is a medicine that contains Trelagliptin Succinate. It is made by Beacon Pharmaceuticals PLC. It belongs to the Dipeptidyl Peptidase-4 (DPP-4) inhibitor group of medicines.
What is Wedica used for?
Trelagliptin Succinate is used for type 2 diabetes mellitus. Doctors prescribe it when metformin, the first line treatment, has not brought blood sugar down to the expected glycemic goals.
What are the side effects of Wedica?
Among 901 domestic clinical trial cases up to the time of approval, 103 cases (11.4%) showed clinical results that included abnormalities and side effects. These were mainly hypoglycemia, nasopharyngitis and elevated lipase.
Can I take Wedica during pregnancy or while breastfeeding?
No studies of Trelagliptin Succinate have been done in women who are pregnant, breast-feeding, possibly pregnant, or planning to become pregnant. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
How should I store Wedica?
Store Trelagliptin Succinate at 25°C. Short periods between 15°C and 30°C are fine.
Is there a cheaper medicine with the same ingredient?
Wedica is already among the lowest-priced brands of Trelagliptin Succinate at this strength.
Do I need a prescription for Wedica?
Wedica is a prescription (Rx) medicine. Take it as your doctor advises.